The first two are associated with a better prognosis in comparison with the last subgroup due to the existence of more TILs in the TME or inside the tumor [80,81] and PD-L1 overexpression, and thus, providing a target for immunotherapy [82]. The gene discussed is CD274; the disease is neoplasm.